Company
Verastem INC
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
1
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Avmapki Fakzynja CO-Pack (Copackaged) approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 8, 2025
Drugs in development (1)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting Phase 3 trials
Largest first.
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerPivotal-lookingRecruiting
Verastem, Inc.Industry
NCT06072781 · 270 participants (planned) · Start Mar 18, 2024 · Primary completion Oct 15, 2028
Drug: avutometinib; Defactinib and 4 more · For: Low Grade Serous Ovarian Cancer
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 105 sites in all
Marketed drugs (1)
Newest FDA action first.
- Avmapki Fakzynja CO-Pack (Copackaged) Avutometinib Potassium, Defactinib Hydrochloride · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.